Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA

Needham analyst Ami Fadia maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $210.00.

Ami Fadia has given his Buy rating due to a combination of factors related to Jazz’s lead oncology asset zanidatamab (Ziihera) in first-line HER2-positive gastroesophageal adenocarcinoma. While the most recent HERIZON-GEA-01 data show median progression-free survival and overall survival that are lower than those seen in earlier, smaller Phase 2 studies, she views this as an expected normalization as the program moves into a larger, more rigorous setting. Importantly, the latest efficacy metrics still compare favorably against the existing standard-of-care regimen from KEYNOTE-811, indicating that Ziihera plus chemotherapy offers a clinically meaningful improvement in both progression-free and overall survival. This competitive differentiation underpins the drug’s commercial potential and supports a constructive outlook on Jazz’s oncology franchise.
Ami Fadia also highlights that Jazz is targeting a supplemental BLA submission for the GEA indication in the first half of 2026, which provides a visible regulatory and potential commercialization catalyst. The ongoing nature of the HERIZON-GEA-01 trial, with additional analyses and a key data update scheduled for early 2026, offers multiple forthcoming data points that could further validate Ziihera’s profile. Together, these elements – better-than-standard-of-care efficacy, a clear regulatory path, and upcoming clinical and investor updates – contribute to her positive risk-reward assessment and underpin the Buy recommendation on Jazz Pharmaceuticals’ shares.

In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $247.00 price target.

Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year.